{
    "nctId": "NCT00215748",
    "briefTitle": "Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel",
    "officialTitle": "Feasibility of A Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Treated With Weekly Docetaxel",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Lung Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "To evaluate the feasibility of a reduced dexamethasone pre-medication dose in elderly lung and breast cancer patients receiving weekly docetaxel therapy with respect to incidence of: Grade 3/4 fluid retention",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* age \u2265 65 years;\n* breast or lung cancer patients to receive docetaxel therapy as per protocol;\n* corticosteroid administration, other than what is prescribed in this protocol, is not permitted during study participation, except topical administration and for adverse events;\n* performance status ECOG 0-2;\n* peripheral neuropathy \u2264 1;\n* adequate kidney and liver functions\n* signed study-specific informed consent\n\nExclusion Criteria:\n\n* Patients who have received an investigational drug within 4 weeks of registration;\n* Prior or concurrent malignancies (other than surgically treated carcinoma in situ;\n* Serious medical or psychiatric illness which would prevent informed consent;\n* Life expectancy \\< 3 months;\n* Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled.",
    "sex": "ALL",
    "minimumAge": "65 Years",
    "stdAges": "OLDER_ADULT"
}